drugset / Trial / NCT02340611
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2 study (the second phase in testing a new drug or drug combination) to see how useful adding investigational drug cediranib to olaparib after disease progression on olaparib alone in patients with ovarian cancer.
Timeline
- Start
- 2015-06
- Primary completion
- 2018-06
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cediranib | Small molecule | 20 mg | Oral |
| Subject | Olaparib | Small molecule | 150 mg | Oral |
| Subject | Olaparib | Small molecule | 200 mg | Oral |